Abstract
An association of hyper- or hypoactivity of endogenous opioids with depressive and schizophrenic psychoses has, to date, not been convincingly demonstrated. Such an assumption could, however, imply an altered sensitivity of structures involved in the mediation of opioid effects. The effects of opioids on pituitary prolactin (PRL)1,2 and luteinizing hormone (LH) release3,4 in man are well described, and there is little doubt that these effects are mediated through distinct opioid receptor populations. We have demonstrated that the partial opioid agonist buprenorphine exerts both antidepressive and antischizophrenic effects.5 We report here on LH and PRL responses of depressed and schizophrenic patients to acute buprenorphine medication in comparison to respective responses of healthy volunteers.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Tolis G, Hikey J, Guyda H. Effect of morphine on serum growth hormone, cortisol, prolactin and thyroid stimulating hormone in man. J Clin Endocrinol Metab 1975; 41: 797–800.
Mendelson JH, Ellinboe J, Mello NK, et al. Buprenorphine effects on plasma luteinizing hormone and prolactin in male heroin addicts. J Pharmacol Exp Ther 1982; 220: 252–255.
Delitala G, Devilla L, Arata L. Opiate receptors and anterior pituitary hormone secretion in man: effect of naloxone infusion. Acta Endocrinol (Copenh) 1981; 97: 150–156.
Veldhuis JD, Worgul TJ, Monsaert R, et al. A possible role for endogenous opioids in the control of prolactin and luteinizing hormone secretion in the human. J Endocrinol Invest 1981; 4: 31–35.
Schmauss C, Emrich HM. Narcotic antagonist and opioid treatment in psychiatry. In Rodgers RJ, Cooper SJ (eds): Endorphins, Opiates and behavioral Processes. London: Wiley 1987; 327–351.
Dum JE, Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br J Pharmacol 1981; 74: 627–633.
Extein J, Pottash ALC, Gold MS, et al. Deficient prolactin response to morphine in depressed patients. Am J Psychiatry 1980; 137: 845–846.
Judd LL, Risch S, Parker DC, et al. The effect of methadone challenge on the prolactin and growth hormone responses of psychiatric patients and normal controls. Psychopharmacol Bull 1983; 18: 204–207.
Robertson AG, Jackman H, Meltzer HY. Prolactin response to morphine in depression. Psychiatry Res 1984; 11: 353–364.
Zis AP, Haskett RF, Albala AA, et al. Prolactin response to morphine in depression. Biol Psychiatry 1985; 20: 287–292.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag New York Inc.
About this chapter
Cite this chapter
Schmauss, C., Pirke, K.M., Bremer, D.E., Weber, M.M., Emrich, H.M. (1989). Luteinizing Hormone and Prolactin Response to Buprenorphine in Depression and Schizophrenia. In: Lerer, B., Gershon, S. (eds) New Directions in Affective Disorders. Springer, New York, NY. https://doi.org/10.1007/978-1-4612-3524-8_60
Download citation
DOI: https://doi.org/10.1007/978-1-4612-3524-8_60
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-96769-1
Online ISBN: 978-1-4612-3524-8
eBook Packages: Springer Book Archive